


EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

Peter W. Hellings^{1,2,3}  | Isam Alobid^{4,5,6} | Wilma T. Anselmo-Lima⁷ |
 Manuel Bernal-Sprekelsen^{8,9}  | Leif Bjerner¹⁰  | Lisa Caulley^{11,12,13} | Adam Chaker¹⁴  |
 Jannis Constantinidis¹⁵  | Diego M. Conti¹⁶  | Eugenio De Corso¹⁷  |
 Martin Desrosiers¹⁸ | Zuzana Diamant^{10,19,20,21}  | Philippe Gevaert³  | Joseph K. Han²² |
 Enrico Heffler^{23,24}  | Claire Hopkins²⁵ | Basile N. Landis²⁶ | Olga Lourenco^{27,28}  |
 Valerie Lund²⁹ | Amber U. Luong³⁰  | Joaquim Mullol³¹  | Anju Peters³²  |
 Carl Philpott^{33,34}  | Sietze Reitsma³⁵  | Dermot Ryan³⁶  | Glenis Scadding³⁷ |
 Brent Senior³⁸ | Peter Valentin Tomazic³⁹  | Elina Toskala⁴⁰ | Thibaut Van Zele³ |
 An-Sofie Viskens^{1,41}  | Martin Wagenmann⁴²  | W. J. Fokkens³⁵ 

Correspondence

W. J. Fokkens, Department of
 Otorhinolaryngology, Amsterdam UMC,
 Amsterdam, The Netherlands.
 Email: w.j.fokkens@amsterdamumc.nl

Abstract

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient,

Abbreviations: AERD, aspirin-exacerbated respiratory disease; ARS, American Rhinologic Society; ATAD, aspirin treatment after desensitization; CRSwNP, chronic rhinosinusitis with nasal polyps; CS, corticosteroids; EGPA, eosinophilic granulomatosis with polyangiitis; EPOS, European position paper on rhinosinusitis and nasal polyps; ERS, European Rhinologic Society; ESS, endoscopic sinus surgery; EUFOREA, European Forum for Research and Education in Allergy and Airway Diseases; INCS, intranasal corticosteroids; NCS, nasal congestion score; N-ERD, non-steroidal anti-inflammatory-exacerbated respiratory disease; NPS, nasal polyp score; NSAIDs, non-steroidal anti-inflammatory drugs; PROM, patient reported outcome measure; QoL, quality of life; SCS, systemic corticosteroids; SNOT-22, Sino-Nasal Outcome Test-22; VAS, visual analogue scale.

For Affiliation refer page on 7

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.

KEYWORDS

aspirin intolerance, biologics, corticosteroids, CRSwNP, sinus surgery

1 | INTRODUCTION

The treatment for patients suffering from uncontrolled severe CRSwNP has been subject to a revolution of care given the growing insight into the underlying pathophysiology over the past two decades, the recommendation to evaluate biomarkers in the context of biologics and the increased awareness of comorbidities.¹⁻³ Chronic rhinosinusitis with nasal polyps (CRSwNP) is present in 1%–2% of the population. The terminology 'CRSwNP' is referring to a phenotype, and based on the increased understanding of underlying pathophysiology, we now rather refer to the term diffuse bilateral CRS.¹ Diffuse bilateral CRS can have a type 2 or non-type 2 endotype and present with or without polyps. In the western world, most of the diffuse bilateral CRS with polyps is of the type 2 endotype. However, in Asia, still a significant, although diminishing percentage of patients present with a non-type 2 endotype.^{4,5}

A better understanding of the underlying inflammatory pathways has led to biologics emerging as an effective novel treatment option in the subtype of patients with type 2 disease. This option supplements the classic advanced treatment options after appropriate medical treatment with intranasal corticosteroid sprays or rinses for CRSwNP, such as oral corticosteroids and endoscopic sinus surgery.^{6,7}

The European Forum for Research and Education in Allergy and Airway Diseases, EUFOREA, is an international not-for-profit organization aiming to prevent and reduce the burden of chronic respiratory diseases via the implementation of optimal care. In the context of CRS, a simplified treatment algorithm was launched, with the aim to educate all healthcare providers dealing with CRS on the treatment options and referral patterns, and to shorten the disease journey for CRS.⁸ EPOS2020 is the 2020 version of the European Position Paper on Chronic Rhinosinusitis and Nasal Polyps. The expert teams of both organizations closely work together to improve management of CRS. Besides baseline treatment with nasal rinses and intranasal corticosteroids, the following five key pillars of specialist care have been used for uncontrolled severe CRSwNP based on personal history and disease journey: oral corticosteroids, primary and revision sinus surgery, biologics and aspirin therapy after desensitization (ATAD).

For several years, biologics have been indicated and are available in a growing number of countries for severe uncontrolled CRSwNP with the need to define specific criteria for the indication. In that context, EUFOREA has defined criteria for the indications of biologics in 2019,^{9,10} which have been finetuned in 2023.¹¹ In contrast to biologics, no international consensus has been reached on the specific academic criteria for the indications of systemic corticosteroids, primary or revision sinus surgery or ATAD. Here, the EUFOREA/EPOS2020 expert panel of CRS supplemented with experts of the

European Rhinology Society (ERS) and American Rhinology Society (ARS) have joined forces to agree on criteria, outcomes, contraindications and considerations in relation to the different treatment options for CRSwNP. The statements of the authors are based on extensive clinical experience and expertise and the current scientific knowledge in relation to each therapeutic option for CRSwNP.

2 | SYSTEMIC CORTICOSTEROIDS

The use of short courses of systemic corticosteroids (SCS) is an important tool in the treatment of severe CRSwNP due to their potent anti-inflammatory effects (see Figure 1).^{1,12} SCS modulate the immune response with suppression of inflammation. These agents reduce the infiltration of inflammatory cells, inhibit the release of pro-inflammatory mediators and attenuate the vasodilation and oedema associated with CRSwNP.^{1,12} The downregulation of inflammatory mediators results in reducing nasal polyp size and improving nasal congestion, smell dysfunction and other sinonasal symptoms.¹²⁻¹⁴

Systemic corticosteroids are an inexpensive and a globally available treatment, with effective reduction of nasal polyp size and rapid improvement of major sinonasal symptoms such as nasal obstruction, loss of smell and nasal discharge in both short- and long-term treatment.¹² SCS are often used in the management of acute exacerbations or as a short-term burst therapy because they can quickly reduce nasal polyp size and alleviate sinonasal symptoms, but evidence, including the optimal dose, is lacking. They are also commonly used for the management of asthma exacerbations in acute care settings, where usually doses of 1 mg/kg prednisolone equivalent to a maximum of 50 mg for 2–7 days are advised.¹⁵⁻¹⁷ Comorbid patients with severe asthma (SA) and CRSwNP usually receive SCS more frequently as they work on both upper and lower airway symptoms, but local (intranasal and inhaled) long-term CS should be preferred.

Unfortunately, the effects of SCS wane shortly after ending treatment.¹⁸ In view of significant systemic side effects observed with repeated short- or long-term courses such as osteoporosis, glaucoma, diabetes, cataract, hypertension, anxiety, insomnia, agitation, risk of adrenal suppression, increased appetite and reflux,^{13,19,20} they are not recommended for maintenance treatment.¹² The EPOS 2020 criteria advise not to prescribe more than two courses of SCS per year because of the cumulative side effects,¹ and Price et al.¹⁹ comparing large groups of asthma patients with and without SCS use even showed a dose-response relationship for cumulative SCS exposure with most adverse



SYSTEMIC CORTICOSTEROIDS

Indications/Criteria	(Relative) Contraindications	Expected Outcome	Considerations
<ul style="list-style-type: none"> Bilateral CRSwNP Severe CRSwNP symptoms despite INCS and saline irrigations Patient willing/able to take oral CS treatment Comorbidities might favour systemic treatment 	<ul style="list-style-type: none"> Medical contraindications for oral CS, e.g. diabetes, glaucoma, osteoporosis Two or more courses in the last year 	<ul style="list-style-type: none"> Short-term treatment: Significant improvement of most/all PROMs during and shortly after treatment Long-term treatment: Significant improvement of all PROMs but NOT RECOMMENDED because of (longterm) side effects Beneficial effect on co-morbidities 	<ul style="list-style-type: none"> Cheap and globally available Optimal dosage unknown Effective on both upper and lower airways, and comorbidities Rapid relapse after the end of treatment Significant general side effects with repeated short or long-term courses Optimal dosage and duration unknown

FIGURE 1 The indications/criteria, (relative) contraindications, expected outcomes and considerations when using systemic corticosteroids in the management of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

outcomes to begin began at cumulative exposures of 1.0 to <2.5 g and for some outcomes like e.g. diabetes mellitus and hypertension already at a cumulative exposures of only 0.5 to <1 g, equivalent to four lifetime SCS courses. Moreover, the willingness of the patient to use SCS should be considered, as some patients might fear the adverse effects.²¹ The use of SCS should be considered extra carefully and weighed against the induced risks in patients suffering from certain conditions such as diabetes, glaucoma or osteoporosis.^{12,22} In routine clinical practice, there is a significant heterogeneity in prescribing systemic steroids by clinicians in terms of type, dosage and treatment duration, partially explained by the lack of universally accepted modes of prescribing of systemic steroids over the years.^{8,20,23,24}

3 | PRIMARY ENDOSCOPIC SINUS SURGERY

Primary ESS is indicated for severe unilateral or bilateral CRSwNP symptoms that persist or recur despite treatment with nasal rinsing, intranasal corticosteroids (INCS) and usually one or more courses of SCS within the preceding 2 years (see Figure 2).^{1,25} Hence, the role of primary ESS managing CRSwNP is critical in cases where first-line medical therapy proves to be insufficient. Despite previous treatments, patients may report significant nasal obstruction as a consequence of large nasal polyps and nasal secretions filling the nasal cavities.

The primary goals of ESS in CRSwNP are to remove the diseased mucosa including nasal polyps, facilitate the delivery of intranasal

corticosteroids to the sinuses, in turn reducing the inflammatory burden of the disease and improving the outcomes of post-EES medical treatment, with the expected outcome of improvement of overall sinonasal symptoms overall. ESS results in limited operative morbidity, rapid recovery (within weeks in most patients) and improved patient outcomes.²⁶ While both the expected outcome and the recurrence rates of ESS vary depending on factors such as the elapsed time since surgery, the extent of the procedure, the presence of comorbidities and the exposure to environmental/occupational irritants, most patients do well after sinus surgery.²⁷⁻²⁹ Furthermore, ESS has shown effectiveness in reducing both upper and lower airway inflammation.³⁰⁻³³ Although evidence is limited, the expert panel advises against performing a polypectomy without a complete ESS, although consensus is lacking about the extent of ESS and whether it should be based on the radiological extent of the disease or the endotype of CRSwNP.

Some patients might, however, fear general anaesthesia and/or ESS and think surgery is only a temporary solution.³⁴ In addition, while in the short-term significant improvements are observed both in upper and lower airway symptoms, regular saline rinsing and INCS use is needed to ensure good results both in the mid-term (one to 5 years post-surgery) and long-term (more than 5 years post-surgery).^{31,35,36} ESS might also be contra-indicated in patients with medical/surgical contra-indications for anaesthesia and surgery, such as in patients with severe uncontrolled asthma. Physicians should also keep in mind that there can be considerable indirect cost related to ESS due to sick leave after the procedure.³⁷



PRIMARY ENDOSCOPIC SINUS SURGERY

Indications/Criteria	Contraindications	Expected Outcome	Considerations
<ul style="list-style-type: none">• Severe CRSwNP symptoms despite nasal rinses and INCS, and 1-2 course(s) of oral CS in the last year• Co-morbidities might favour surgery• Patient willing/able to undergo surgery	<ul style="list-style-type: none">• Medical/surgical contraindications for anaesthesia/surgery	<ul style="list-style-type: none">• Short-term outcome (first year): Significant• Mid-term outcome (1-5 years): Moderate, local INCS should be continued• Long-term outcome (> 5 yr): Recurrence rates depend on endotype, presence of comorbidities, and environmental/occupational exposure• Beneficial effects on comorbidities	<ul style="list-style-type: none">• Polypectomy without complete ESS is not recommended• Impact on direct postoperative QOL and work• Continued use of topical corticosteroids (rinses/sprays) needed to maintain the surgical outcomes.• Risk of serious complications

FIGURE 2 The indications/criteria, (relative) contraindications, expected outcomes and considerations when using primary endoscopic sinus surgery in the management of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

4 | REVISION ENDOSCOPIC SINUS SURGERY

Primary ESS provides effective relief and a good control of symptoms in the majority of the patients (see Figure 3).²⁷ However, several studies have highlighted that a percentage of patients remain uncontrolled in the post-operative phase despite optimal medical care and good compliance with local treatment.^{18,27,38,39} In case of persistent uncontrolled CRSwNP, physicians need to explore the varying reasons for relapse or persistence which may be related to such factors as diagnosis, treatment, patient and surgery performed, before considering the next step of care for CRSwNP.⁴⁰ The goals of revision ESS should be carefully determined and may include the removal of obstructing polyps, addressing any residual anatomical issues that may contribute to recurrence such as scar tissue or insufficiently opened sinuses or the presence of complications such as mucocoele formation. In the shared decision-making process, clinicians and patients must consider symptomatology, goals of the revision surgery, impact of the surgery on the patient (including the potential for an increased risk of intra-operative complications), post-operative compliance to anti-inflammatory treatment and the chronicity of the disease.^{24,41}

Revision ESS can be more challenging than the primary surgery due to scarring and altered anatomy from previous procedures⁴² resulting in a higher risk of complications,⁴³ and one can consider referring to a rhinologist or more experienced sinus surgeon. The surgeon must carefully assess the extent of inflammation, the extent of the surgery

performed earlier, the presence of fibrosis and chronic osteitis and the potential impact on adjacent structures and include the higher complication risk in the decision process. This in turn may lead to a longer recovery period and higher indirect costs due to sick leave.^{31,37,44}

5 | ASPIRIN TREATMENT AFTER DESENSITIZATION

Aspirin-exacerbated/non-steroidal anti-inflammatory-exacerbated respiratory disease (AERD/N-ERD) is a subset of CRSwNP characterized by severe CRSwNP, asthma and hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) (see Figure 4).

Aspirin treatment after desensitization (ATAD) is a specialized procedure designed to induce tolerance to aspirin and NSAIDs in AERD/N-ERD patients. It involves the gradual administration of increasing doses of aspirin under controlled conditions until the patient reaches a therapeutic dose. This process allows N-ERD patients to take aspirin safely and reach the potential anti-inflammatory benefits associated with its use.^{45,46}

Aspirin treatment after desensitization has been shown to significantly reduce the size of nasal polyps in N-ERD patients.^{47,48} The anti-inflammatory effects of aspirin contribute to reduced polyp burden and improved nasal airflow.⁴⁹ ATAD has also been associated with a reduction in asthma exacerbations and improved lung function in N-ERD patients with coexisting asthma.⁵⁰ Aspirin treatment



REVISION ENDOSCOPIC SINUS SURGERY

Indications/Criteria	Contraindications	Expected Outcome	Considerations
<ul style="list-style-type: none"> Recurrent bilateral severe CRSwNP despite optimal medical care and good compliance Patient willing/able to undergo revision surgery 	<ul style="list-style-type: none"> Medical/surgical contraindications for anaesthesia/surgery 	<ul style="list-style-type: none"> Short-term outcome (first year): Significant Mid-term outcome (1-5 years): Moderate, local INCS should be continued Long-term outcome (> 5 yr): Recurrence rates depend on endotype, presence of comorbidities, and environmental/occupations exposure Beneficial effects on comorbidities 	<ul style="list-style-type: none"> Goals of surgery should be clear to surgeon and patient Continued use of topical corticosteroids (rinses/sprays) needed to maintain the surgical outcomes. Increased complication risk with revision surgery

FIGURE 3 The indications/criteria, (relative) contraindications, expected outcomes and considerations when using revision endoscopic sinus surgery in the management of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).



ASPIRIN TREATMENT AFTER DESENSITIZATION (ATAD)

Indications/Criteria	Contraindications	Expected Outcome	Considerations
<ul style="list-style-type: none"> Severe CRSwNP (with asthma) and aspirin/NSAID intolerance 	<ul style="list-style-type: none"> Contra-indication for long term aspirin/NSAID usage (gastrointestinal) 	<ul style="list-style-type: none"> Mid-term outcomes (1y therapy): Significant effect on sinonasal and asthma symptoms Long-term outcome (> 1yr): Significant effect on QoL, total nasal symptom score and asthma symptoms 	<ul style="list-style-type: none"> Low direct cost, and self-administration -Desensitization needs clinical observation period Reduced need for oral CS and sinus surgery

FIGURE 4 The indications/criteria, (relative) contraindications, expected outcomes and considerations when using aspirin treatment after desensitization (ATAD) in the management of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

may also improve the response of nasal polyps to corticosteroid therapy, potentially reducing the need for systemic corticosteroids.⁴⁷ Aspirin treatment may also improve the response of nasal polyps to corticosteroid therapy, potentially reducing the need for systemic corticosteroids.⁴⁷

The EUFOREA's expert panel advises considering ATAD in patients with bilateral CRSwNP with comorbid asthma and history of aspirin/NSAID intolerance, especially when there is a need for aspirin-antiplatelet therapy or NSAIDs to treat chronic inflammatory conditions. ATAD is a therapy with a low direct cost and a significant

effect on patient's QoL, total nasal symptom score and asthma symptoms of the patient.^{1,50}

Aspirin treatment after desensitization offers the most benefit in patients with recent debulking sinus surgery by preventing the recurrence of nasal polyps and reducing the need for SCS and ESS⁵¹ but is associated with a risk of hypersensitivity reactions and/or gastrointestinal bleeding.¹ ATAD is a specialized medical procedure that demands careful oversight and management by an experienced healthcare provider.

After successful aspirin desensitization, close monitoring of patients is essential to ensure continued tolerability of aspirin and NSAIDs. Patients should be regularly assessed for symptom improvement, polyp recurrence and asthma control. Maintenance aspirin therapy is always required to maintain the desensitized state and its' anti-inflammatory benefits.

Aspirin treatment after desensitization is contra-indicated for patients with a severe hypersensitivity reaction after aspirin ingestion, i.e. an asthma attack, poorly controlled asthma (FEV1 <70%), pregnancy, history of eosinophilic oesophagitis, gastric and/or peptic ulcers or a history of bleeding disorders or coagulopathy.⁴⁷

6 | BIOLOGICS

In recent years, there has been significant progress in understanding the underlying immune mechanisms that drive CRSwNP leading to the development of targeted biologic therapies (see Figure 5). For CRSwNP,

biologics focus primarily on neutralizing specific pro-inflammatory type-2 cytokines, such as interleukin (IL)-4/IL-13,^{52,53} or IL-5,^{6,54,55} or mediators like IgE,⁵⁶ which are central in promoting the recruitment and activation of inflammatory cells in CRSwNP. By blocking the activity of these mediators, biologics modulate the immune response and reduce the chronic inflammation associated with the disease (including comorbidities).⁵⁷ Biologics have been shown to reduce the size of nasal polyps, improve nasal obstruction, relieve symptoms, improve the sense of smell and improve the quality of life.^{48,58-61}

Based on EPOS 2020¹ and the EPOS/EUFOREA update on biologics 2023,¹¹ the EUFOREA expert panels recommend biologics in CRSwNP patients that are uncontrolled despite appropriate medical treatment and appropriate sinus surgery and who fulfil 3 of 5 criteria (presence of Type 2 inflammation, regular need for SCS/contraindications to SCS, significant impact on QoL, loss of smell and comorbid asthma). Biologics are an effective treatment with an expected improvement in the short-term (16th week to 24th week), of at least one of the following symptom/scores: sense of smell, the nasal congestion score (NCS), the nasal polyp score (NPS), the Sino-Nasal Outcome Test (SNOT-22) and the visual analogue scale (VAS).⁶¹⁻⁶⁵ For dupilumab, long-term (up to 2 years) beneficial effects have been reported.^{59,61} Beneficial effects on comorbidities may be confirmed at any point of the treatment, based on the aforementioned definitions and a reduction in the need for SCS and ESS can be observed.^{66,67}

Biologics have a good safety profile but are contra-indicated in patients with hypersensitivity to the specific monoclonal antibodies or any drug components. Specific considerations should be taken in



BIOLOGICS

Indications/Criteria	(Relative) Contraindications	Expected Outcome	Considerations
<p>Bilateral severe CRSwNP in patient who had ESS*, with ≥ 3 of 5 criteria:</p> <ul style="list-style-type: none"> Evidence of Type 2 inflammation Need for systemic corticosteroid or contraindication to systemic corticosteroids Significantly impaired quality of life Significant loss of smell (Anosmic on smell test) Diagnosis of co-morbid asthma Patient willing/able to take biologics 	<ul style="list-style-type: none"> Side effects (arthralgia, dry eyes, local injection side reaction) Hypersensitivity to monoclonal antibodies Pregnancy Hypereosinophilic syndrome Parasitic infections 	<ul style="list-style-type: none"> Short-term outcome (16w-24w): Significant Mid-term - long-term outcomes (>1yr therapy): Significant Beneficial effects on comorbidities 	<ul style="list-style-type: none"> High direct cost Patient preference Safe treatment, with some relative medical contraindications and product-dependent safety data Self-administration Reduced need for oral corticosteroids and sinus surgery local availability/affordability

* Exceptional circumstances excluded (e.g., not fit for surgery)

FIGURE 5 The indications/criteria, (relative) contraindications, expected outcomes and considerations when using biologics in the management of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

pregnancy since there is not yet enough data to rule out foetal harm or other side effects.^{68,69} In this regard, the best data are available for omalizumab, where no increase in congenital anomalies has been demonstrated to date.⁶⁸⁻⁷⁰ Therefore, the EUFOREA group advises to carefully counsel pregnant patients and female patients who wish to have children and to only continue the biologic if there are very strong reasons to do so.⁶⁸⁻⁷⁰ Two other reasons to closely monitor patients/discontinue a biologic are hypereosinophilia (mainly dupilumab⁷¹⁻⁷³) and helminth infections if patients do not respond to anti-helminth treatment.^{74,75}

Overall, biologics are a safe and effective treatment option in most severe uncontrolled CRSwNP patients, with the need to properly select the patient given the high direct costs and the necessity of repeated self-administration.^{48,59,61,76}

7 | CONCLUSION

This overview of treatment options for severe uncontrolled CRSwNP with indications and considerations for clinicians and patients aims to provide a further step forward in the personalization of care in CRSwNP. Ideally, patients can be offered the option of different strategies beyond SCS and primary/revision surgery, such as ATAD or biologic therapy, thereby benefiting from a personalized treatment plan.

AUTHOR CONTRIBUTIONS

PH and WF developed the first version of the manuscript. All authors developed, revised and critically reviewed the manuscript and provided final approval of the version submitted for publication. All authors participated in the development of the manuscript.

AFFILIATIONS

- ¹Department of Microbiology and Immunology, Allergy and Clinical Immunology Research unit, KU Leuven, Leuven, Belgium
- ²Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium
- ³Department of Otorhinolaryngology, Upper airways research laboratory, Ghent University, Ghent, Belgium
- ⁴Rhinology and Skull Base Unit, ENT Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
- ⁵Clinical and Experimental Respiratory Immunoallergy, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- ⁶Center of Biomedical Research in Respiratory Diseases (CIBERES), Barcelona, Spain
- ⁷Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School-University of Sao Paulo, Brazil
- ⁸Department of Otorhinolaryngology, University of Barcelona, Barcelona, Spain
- ⁹Department of Otorhinolaryngology, Hospital Clínic Barcelona, Barcelona, Spain
- ¹⁰Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden
- ¹¹Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Ontario, Canada
- ¹²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- ¹³Institut for Klinisk Medicin, Aarhus University, Aarhus, Denmark

- ¹⁴Dept. of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
- ¹⁵1st Department of Otorhinolaryngology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
- ¹⁶The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium
- ¹⁷Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli University Hospital Foundation, IRCSS, Rome, Italy
- ¹⁸Department of ORL-HNS, Université de Montréal, Montreal, Canada
- ¹⁹Department of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium
- ²⁰Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- ²¹Department of Clinical Pharmacy & Pharmacology, University in Groningen, University Medical Center Groningen, Groningen, Netherlands
- ²²Department of Otolaryngology & Head and Neck Surgery, Eastern Virginia Medical School, Virginia, USA
- ²³Personalized Medicine, Asthma and Allergy—IRCCS Humanitas Research Hospital, Rozzano, Italy
- ²⁴Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- ²⁵Ear, Nose and Throat Department, Guys and St. Thomas Hospital, London, UK
- ²⁶Rhinology-Olfactology Unit, Department of Otorhinolaryngology Head and Neck Surgery, University Hospital of Geneva, Geneva, Switzerland
- ²⁷FCS-UBI, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
- ²⁸CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
- ²⁹Royal National Ear, Nose and Eastman Dental Hospital, London, UK
- ³⁰Otolaryngology-HNS, McGovern Medical School of the University of Texas Health Science Center, Houston, Texas, USA
- ³¹Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain
- ³²Division of Allergy and Immunology and Northwestern Sinus Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- ³³Rhinology & ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, UK
- ³⁴Norfolk & Waveney ENT Service, James Paget and Norfolk & Norwich University Hospitals, Norfolk, UK
- ³⁵Department of Otorhinolaryngology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands
- ³⁶Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
- ³⁷Royal National ENT Hospital, London and Division of Immunity and Infection, University College, London, UK
- ³⁸Department of Otolaryngology/Head and Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA
- ³⁹Department of General Otorhinolaryngology, H&N Surgery, Medical University of Graz, Graz, Austria
- ⁴⁰Otolaryngology-HNS, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- ⁴¹Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- ⁴²Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany

ACKNOWLEDGEMENTS

To Tania Rodrigues Lopes and Elizabeth Van Staeyen for their valuable help in designing the figures in this manuscript.

CONFLICT OF INTEREST STATEMENT

Isam Alobid: Consultant for Sanofi, Novartis, AstraZeneca, GSK, Viartis, Salvat, Storz, Olympus, Metronic, MSD and Roche. **Wilma Anselmo Lima:** No conflicts of interest to declare in relation to

this initiative. **Manuel Bernal-Sprekelsen:** Speaker honorarium from GSK Spain, Olympus Europe, Viatrix Spain, Sanofi Spain. Editor-in-Chief Eur.Arch. ORL-HNS. **Leif Bjermer:** Hourly fee for medical consultancy from Acucort, Airsonett, Astrazeneca, Birc and Phargentis. Lecture fees from AstraZeneca, GlaxoSmithKlein, Birc and Sanofi. Advisory board at AstraZeneca, GSK and Sanofi. **Lisa Caulley:** No conflicts of interest to declare in relation to this initiative. **Adam Chaker:** Dr. Chaker reports grants, speaker honoraria, consultancy or advisory fees and/or research support and other all via Technical University of Munich from Allergopharma, ALK Abello, Astra Zeneca, Bencard/Allergen Therapeutics, GSK, Novartis, LETI, Roche, Zeller, Sanofi Genzyme/Regeneron, Thermo Fisher, European Institute of Technology (EIT Health) and Federal Ministry of Research and Education Germany. **Jannis Constantinidis:** Has received honoraria for consultancy from GSK. **Diego Conti:** No conflicts of interest to declare in relation to this initiative. **Eugenio De Corso:** Received fee for consultation, speaker activity, advisory board by Sanofi, Regeneron, GSK, Novartis and Astrazeneca. **Martin Desrosiers:** Received fee for consultation, speaker activity, advisory board by sanofi/Regeneron, GSK. Research support, sanofi/Regeneron, GSK. Equity holder, Probionase Therapies Inc. **Zuzana Diamant:** In the past 3 years, ZD received speaker or consultant honoraria and/or served on advisory boards at: Antabio, Foresee Pharmaceuticals, GlaxoSmithKline, Hippo-Dx, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the submitted work. From 2012 to 2020 she acted as Director Respiratory & Allergy Research at QPS-Netherlands; in 2019-ongoing, QPS-Netherlands received a European grant from ERA4TB (4 years) and funding from Foresee Pharmaceuticals for early respiratory studies. **W. J. Fokkens:** The department of Otorhinolaryngology of the Amsterdam University Medical centre, location AMC received grants for research in Rhinology from: ALK, Allergy Therapeutics, Chordate, Novartis, EU, GSK, MYLAN, Sanofi-Aventis and Zon-MW. Wytske Fokkens received consultation and/or speaker fees from Dianosis, GSK, Novartis and Sanofi-Aventis/Regeneron and is chair of EPOS and board member of EUFOREA. **Philippe Gevaert:** Has participated in advisory boards and received speaker fees from ALK-Abelló, Argenx, AstraZeneca, Genentech, GSK, Novartis, Regeneron, Roche, Sanofi Genzyme and Stallergenes Greer. **Joseph Han:** Research consultant for Sanofi, Regeneron, GlaxoSmithKline and AstraZeneca. **Enrico Heffler:** Speaker's fee and Advisory Board participation for: Sanofi; Regeneron; GSK; Astrazeneca; Novartis; Chiesi; Stallergenes-Greer; Almirall; Bosch. **Peter Hellings:** Consultant and recipient of lecture fees and/or research grants from Sanofi, Regeneron, Novartis, GSK, ALK and Viatrix. **Claire Hopkins:** Ad boards—GSK, Sanofi Regeneron, Lilly. **Basile Landis:** No conflicts of interest to declare in relation to this initiative. **Olga Lourenco:** No conflicts of interest to declare in relation to this initiative. **Valerie Lund:** Honoraria for speaking and advisory boards: Abbot, Alcimed, Evidera, GRG, GSK, Novartis, Sanofi. Editor, Cummings Otorhinolaryngology, Elsevier. **Amber Luong:** Consultant or member of scientific advisory boards for ENTvantage

Dx, Lyra Therapeutics, Maxwell Biosciences, Medtronic, Sanofi, SoundHealth and Stryker. **Joaquim Mullol:** Joaquim Mullol is or has been member of national and international scientific advisory boards, consulting, received fees for lectures and grants for research projects or clinical trials from AstraZeneca, Genentech-Roche, GSK, LETI, Lilly, Menarini, MSD, Mitsubishi-Tanabe, NOUCOR/Uriach Group, Novartis, OPTINOSE, Proctor & Gamble, Regeneron Pharmaceuticals Inc., Sanofi-Genzyme, UCB Pharma and Viatrix/MEDA Pharma. **Anju Peters:** Received fee for consultation and advisory board by Sanofi Regeneron, GSK, AstraZeneca, Merck and Optinose. Research support to the institution by Sanofi Regeneron, Merck and AstraZeneca. **Carl Philpott:** Honoraria for speaker/advisory boards: GSK, Sanofi, Olympus, Abbott, Stryker. Grants from NIHR. Trustee of Fifth Sense. **Sietze Reitsma:** Has acted as a consultant and/or advisory board member for Sanofi, GSK and Novartis. The department of Otorhinolaryngology and Head/Neck Surgery of the Amsterdam UMC has received research funding from Sanofi, GSK and Novartis. **Dermot Ryan:** No conflicts of interest to declare in relation to this initiative. **Glenis Scadding:** Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi Regeneron and Viatrix. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Board member and AR lead for EUFOREA and Chair/member Data Monitoring Committees on SLIT for ALK. **Brent Senior:** Lyra Therapeutics: consultant, Stryker: Consultant, Neurent: consultant, MCSP: consultant and American Rhinologic Society: VP of Development and Strategy. **Valentin Tomazic:** No conflicts of interest to declare in relation to this initiative. **Elina Toskala:** Consultation fees and research grants: GSK, Sanofi, Aerin, Optinose, Medtronic. **Thibaut Van Zele:** Honoraria for consultancy and courses for Medtronic. **An-Sofie Viskens:** No conflicts of interest to declare in relation to this initiative. **Martin Wagenmann:** Fees for lectures and/or participation in scientific advisory boards: ALK-Abelló, AstraZeneca, CSL Behring, Genzyme, GSK, Infectopharma, LETI Pharma, Novartis, Regeneron, Sanofi, Stallergenes. Grants (to institution): ALK-Abelló, AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi-Aventis, Takeda.

ORCID

Peter W. Hellings  <https://orcid.org/0000-0001-6898-688X>

Manuel Bernal-Sprekelsen  <https://orcid.org/0000-0001-8191-9833>

Leif Bjermer  <https://orcid.org/0000-0002-3441-8099>

Adam Chaker  <https://orcid.org/0000-0002-5117-4073>

Jannis Constantinidis  <https://orcid.org/0000-0002-2369-993X>

Diego M. Conti  <https://orcid.org/0000-0002-8896-495X>

Eugenio De Corso  <https://orcid.org/0000-0001-5761-7018>

Zuzana Diamant  <https://orcid.org/0000-0003-0133-0100>

Philippe Gevaert  <https://orcid.org/0000-0002-1629-8468>

Enrico Heffler  <https://orcid.org/0000-0002-0492-5663>

Olga Lourenco  <https://orcid.org/0000-0002-8401-5976>

Amber U. Luong  <https://orcid.org/0000-0001-6078-8010>

Joaquim Mulla  <https://orcid.org/0000-0003-3463-5007>

Anju Peters  <https://orcid.org/0000-0003-0745-2379>

Carl Philpott  <https://orcid.org/0000-0002-1125-3236>

Sietze Reitsma  <https://orcid.org/0000-0003-1734-2632>

Dermot Ryan  <https://orcid.org/0000-0002-4115-7376>

Peter Valentin Tomazic  <https://orcid.org/0000-0001-6445-4800>

An-Sofie Viskens  <https://orcid.org/0000-0001-9757-7807>

Martin Wagenmann  <https://orcid.org/0000-0002-9734-0241>

W. J. Fokkens  <https://orcid.org/0000-0003-4852-229X>

REFERENCES

- Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. *Rhinology*. 2020;58(Suppl S29):1-464.
- Hellings PW, Akdis CA, Bachert C, et al. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. *Rhinology*. 2017;55(3):202-210.
- Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. *Int Forum Allergy Rhinol*. 2021;11(3):213-739.
- Katotomichelakis M, Tantilipikorn P, Holtappels G, et al. Inflammatory patterns in upper airway disease in the same geographical area may change over time. *Am J Rhinol Allergy*. 2013;27(5):354-360.
- Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. *J Allergy Clin Immunol*. 2017;140(5):1230-1239.
- Bachert C, Hellings PW, Lund VJ, et al. Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP. *Rhinology*. 2022;60(6):474-478.
- Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol*. 2020;145(3):725-739.
- Hellings PW, Fokkens WJ, Orlandi R, et al. The EUFOREA pocket guide for chronic rhinosinusitis. *Rhinology*. 2023;61(1):85-89.
- Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. *J Allergy Clin Immunol*. 2021;147(1):29-36.
- Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. *Allergy*. 2019;74(12):2312-2319.
- Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. *Rhinology*. 2023;61(3):194-202.
- Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. *Clin Transl Allergy*. 2020;10:1.
- Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AG. Short-course oral steroids alone for chronic rhinosinusitis. *Cochrane Database Syst Rev*. 2016;4(4):Cd011991.
- Deng J, Wang Z, Xu Z, et al. Blood eosinophils to direct oral corticosteroid treatment for patients with nasal polyps—an open label, non-inferiority, randomized control trial. *Rhinology*. 2023;61(4):328-337.
- GINA Main Report 2023. 2023.
- Banoth B, Verma A, Bhalla K, Khanna A, Holla S, Yadav S. Comparative effectiveness of oral dexamethasone vs. oral prednisolone for acute exacerbation of asthma: a randomized control trial. *J Family Med Prim Care*. 2022;11(4):1395-1400.
- Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. *Cochrane Database Syst Rev*. 2016;2016(5):Cd011801.
- van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. *J Allergy Clin Immunol*. 2010;125(5):1069-1076.e4.
- Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. *J Asthma Allergy*. 2018;11:193-204.
- de Corso E, Pipolo C, Cantone E, et al. Survey on use of local and systemic corticosteroids in the management of chronic rhinosinusitis with nasal polyps: identification of unmet clinical needs. *J Pers Med*. 2022;12(6):897.
- Hopkins C, Surda P, Walker A, et al. EPOS 4 patients. *Rhinology*. 2021;59:1-57.
- Amiche MA, Abtahi S, Driessen JHM, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. *Arch Osteoporos*. 2018;13(1):30.
- Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. *Laryngoscope*. 2019;129(9):1969-1975.
- de Corso E, Settini S, Montuori C, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review. *Acta Otorhinolaryngol Ital*. 2023;43(Suppl. 1):S3-s13.
- Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. *Rhinology*. 2016;54(2):117-128.
- de Prins L, Raap U, Mueller T, et al. White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA. *Front Allergy*. 2022;3:889221.
- Loftus CA, Soler ZM, Koochakzadeh S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. *Int Forum Allergy Rhinol*. 2020;10(2):199-207.
- Hox V, Delrue S, Scheers H, et al. Negative impact of occupational exposure on surgical outcome in patients with rhinosinusitis. *Allergy*. 2012;67(4):560-565.
- Kim DH, Han JS, Kim GJ, Basurrah MA, Hwang SH. Clinical predictors of polyps recurring in patients with chronic rhinosinusitis and nasal polyps: a systematic review and meta-analysis. *Rhinology*. 2023;30:62-68.
- Lourijsen ES, Reitsma S, Vleming M, et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. *Lancet Respir Med*. 2022;10(4):337-346.
- Vlaminck S, Acke F, Prokopakis E, et al. Surgery in nasal polyp patients: outcome after a minimum observation of 10 years. *Am J Rhinol Allergy*. 2021;35(4):449-457.
- Cao Y, Hong H, Sun Y, et al. The effects of endoscopic sinus surgery on pulmonary function in chronic rhinosinusitis patients with asthma: a systematic review and meta-analysis. *Eur Arch Otorhinolaryngol*. 2019;276(5):1405-1411.
- Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis. *Int Forum Allergy Rhinol*. 2013;3(10):788-794.
- Vennik J, Eyles C, Thomas M, et al. Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care. *BMJ Open*. 2019;9(4):e022644.
- Hamada K, Oishi K, Chikumoto A, et al. Impact of sinus surgery on type 2 airway and systemic inflammation in asthma. *J Asthma*. 2021;58(6):750-758.
- Arancibia C, Langdon C, Mulla J, Alobid I. Twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps. *Rhinology*. 2022;60(4):261-269.

37. van der Lans RJL, Hopkins C, Senior BA, Lund VJ, Reitsma S. Biologicals and endoscopic sinus surgery for severe uncontrolled chronic rhinosinusitis with nasal polyps: an economic perspective. *J Allergy Clin Immunol Pract*. 2022;10(6):1454-1461.
38. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. *Allergy*. 2017;72(2):282-290.
39. Phillips KM, Singerman KW, Sedaghat AR. Individual symptom visual analogue scale severity scores for determining EPOS guideline-based chronic rhinosinusitis disease control. *Rhinology*. 2022;60(3):229-235.
40. Viskens AS, Wils T, Van Bulck P, Cools L, Vanderveken O, Hellings PW. Multiple reasons underlying uncontrolled disease in the majority of chronic rhinosinusitis patients. *Front Allergy*. 2022;3:1048385.
41. Fokkens WJ, Pugin B, Bachert C, et al. Rhinology future debates 2017 by EUFOREA: novel treatments and surgical solutions in rhinology. *Clin Otolaryngol*. 2018;43(6):1429-1438.
42. Bewick J, Egro FM, Masterson L, Javer AR, Philpott CM. Anatomic findings in revision endoscopic sinus surgery: case series and review of contributory factors. *Allergy Rhinol (Providence)*. 2016;7(3):151-157.
43. Krings JG, Kallogjeri D, Wineland A, Nepple KG, Piccirillo JF, Getz AE. Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis. *Laryngoscope*. 2014;124(4):838-845.
44. Hellings PW. From prevention to optimal treatment in chronic rhinosinusitis. *Rhinology*. 2018;56(4):305-306.
45. van der Lans RJL, Fokkens WJ, Reitsma S. Therapeutic options for chronic rhinosinusitis in N-ERD patients. *Front Allergy*. 2021;2:734000.
46. Yong M, Wu YQ, Howlett J, Ballreich J, Walgama E, Thamboo A. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. *Int Forum Allergy Rhinol*. 2021;11(12):1626-1636.
47. van Broeck D, Steelant B, Scadding G, Hellings PW. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)? *Front Allergy*. 2023;4:1080951.
48. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. *J Allergy Clin Immunol*. 2022;149(4):1286-1295.
49. Pendolino AL, Scadding GK, Scarpa B, Andrews PJ. A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease. *Eur Arch Otorhinolaryngol*. 2022;279(5):2473-2484.
50. Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2021;147(3):827-844.
51. Aydin Ö, Atmış E, Anadolu Y, Yorulmaz İ, Çelik GE. Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. *J Asthma*. 2023;60(6):1131-1140.
52. Lee SE, Hopkins C, Mullol J, et al. Dupilumab improves health related quality of life: results from the phase 3 SINUS studies. *Allergy*. 2022;77(7):2211-2221.
53. Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. *Allergy*. 2022;77(4):1231-1244.
54. Hopkins C, Han JK, Lund VJ, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. *Rhinology*. 2023;61(2):108-117.
55. Fokkens WJ, Mullol J, Kennedy D, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis. *Allergy*. 2023;78(3):812-821.
56. Roland LT, Wise SK, Wang H, Mehta C, DelGaudio JM, Levy JM. Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis. *Int Forum Allergy Rhinol*. 2022;12(3):310-312.
57. Striz I, Golebski K, Strizova Z, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. *Clin Sci (Lond)*. 2023;137(9):727-753.
58. Kariyawasam HH, Chandrasekharan DP, Jacques T, et al. Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. *Rhinology*. 2023;61(2):98-107.
59. de Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL). *Allergy*. 2023;78(10):2669-2683.
60. Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. *Rhinology*. 2022;60(6):435-443.
61. van der Lans RJL, Otten JJ, Adriaensen G, et al. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. *Allergy*. 2023;78:2684-2697.
62. Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. *Rhinology*. 2021;59(2):151-163.
63. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-1650.
64. Lans R, Fokkens WJ, Adriaensen G, Hoven DR, Drubbel JJ, Reitsma S. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. *Allergy*. 2022;77(2):670-674.
65. Xu X, Reitsma S, Wang Y, Fokkens WJ. Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. *Allergy*. 2022;77(12):3593-3605.
66. Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. *Allergy*. 2021;76(8):2337-2353.
67. Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. *Rhinology*. 2021;59(3):301-311.
68. Shakuntalla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. *J Allergy Clin Immunol Pract*. 2022;10(12):3149-3155.
69. Pfaller B, José Yepes-Nuñez J, Agache I, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. *Allergy*. 2021;76(1):71-89.
70. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. *J Allergy Clin Immunol*. 2020;145(2):528-536.e1.
71. Ryser FS, Yalamanoglu A, Valaperti A, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. *Allergy*. 2023;78(10):2712-2723.
72. Soyka MB, Ryser FS, Brühlmann C, et al. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. *Allergy*. 2023;78(4):1036-1046.
73. Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. *Allergy*. 2021;76(9):2920-2923.

74. Lifar P, Montastruc F, Reber LL, Magnaval JF, Guilleminault L. Parasitic infections and biological therapies targeting type 2 inflammation: a VigiBase study. *Am J Respir Crit Care Med*. 2023;207(9):1253-1255.
75. Rothenberg ME, Roufosse F, Faguer S, et al. Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and interleukin-5. *J Allergy Clin Immunol Pract*. 2022;10(9):2367-2374.e3.
76. Hopkins C. Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps. *Rhinology*. 2022;60(3):162-168.

How to cite this article: Hellings PW, Alobid I, Anselmo-Lima WT, et al. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care. *Allergy*. 2023;00:1-11. doi:[10.1111/all.15982](https://doi.org/10.1111/all.15982)